163 results about "Glucose uptake" patented technology

The present invention relates to weight control, control of body fat and food intake, and provides useful methods for treating, inter alia, obesity, diabetes and insulin insensitivity, and conditions, diseases, and disorders relating thereto. The invention also relates to methods of identifying useful compounds relating to weight loss, food intake, diabetes, and obesity, among other things, based on the discovery that inhibiting Kv1.3 activity mediates decreased food intake, weight loss, decreased body fat, increase glucose uptake, and increased insulin sensitivity, among other things.

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

Compositions and methods are provided to increase glucose uptake in a cell as well as to treat a patient suffering from a condition or disorder associated with AMPK regulation. Particularly contemplated compositions include a compound that is isolated from a plant that has AICAR-like activity. In another aspect of the invention, contemplated compositions comprise a non-insulin compound that has AICAR-like activity and activates AMPK in a cell.

An implanted medical device may detect the onset of impaired glucose tolerance or Type II diabetes. The implanted medical device may have additional functionality. For example, the implanted medical device may be a pacemaker or a pressure monitor, but may also monitor insulin-mediated glucose uptake by processing electrical signals from the heart. An implanted medical device that monitors insulin-mediated glucose uptake may be implanted in a patient who has not been diagnosed with impaired glucose tolerance or Type II diabetes, and may give the patient early warning if these conditions develop.

The invention relates to compositions comprising at least two inhibitors selected from the group consisting of an alpha amylase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose uptake.

The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

The invention provides a method for preparing total triterpenoids with a hypoglycemic effect from leaves of Cyclocarya paliurus. The leaves of the Cyclocarya paliurus are taken as a raw material and subjected to extraction with an ethanol-water mixed solvent and liquid-liquid extraction with an organic solvent, polyamide column chromatography based organic solvent elution and macroporous resin column chromatography based ethanol-water elution are performed for separation and purification, and high-purity total triterpenoids can be obtained. Research proves that main components such as arjunolic acid, asiatic acid, cyclocaric acid B and a compound 4 in the total triterpenoids can effectively increase glucose uptake of 3T3-L1 adipose cells and have antidiabetic activity, and the total triterpenoids and the main components of the total triterpenoids can be used for preparing products such as hypoglycemic and antidiabetic drugs, health food and functional food. The method for preparing thetotal triterpenoids from the leaves of Cyclocarya paliurus and an application of the total triterpenoids and the compound 4 to preparation of the antidiabetic drugs are developed, reference is provided for popularization, utilization and deep processing of traditional Chinese medicinal materials, and a new application direction is provided.

Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

The invention provides a preparation method and application of total flavone and total polysaccharide in cyclocarya paliurus leaves. The method comprises the steps of taking cyclocarya paliurus leavesas raw materials, executing extraction by an ethanol-water solvent, executing extraction by an organic solvent, executing elution by a chromatographic column and by macroporous resin to obtain totalflavone, conducting extraction on cyclocarya paliurus leaf dregs by hot water, executing precipitation, removing protein, and adsorbing impurities by macroporous resin to obtain total polysaccharide.Studies show that the total triterpenes, the total flavones, the total polysaccharides and their composition prepared by the method can effectively increase glucose uptake of 3T3-L1 adipocytes, obviously reduce the fasting blood glucose level of the hereditary diabetes db/db mice, has antidiabetic activity, and can be used for preparing products such as antidiabetic medicines, health foods, functional foods and the like for reducing blood sugar. The invention develops the comprehensive preparation method of total flavones and total polysaccharides in cyclocarya paliurus leaves and applicationof the mehtod in resisting diabetes, and provides a basis and a new application direction for popularization, utilization and deep processing of traditional Chinese medicinal materials and new food raw materials.

Novel, safe, and highly effective agents for preventing insulin resistance and for preventing metabolic syndrome that contain astaxanthin and/or an ester thereof as an active component are provided. Even when a high-fat diet intake is continued, insulin resistance and subsequent hyperinsulinemia are suppressed by using the agent for preventing insulin resistance and the agent for preventing metabolic syndrome according to the present invention. Furthermore, suppression of fat degradation is thus inhibited and promotion of fat synthesis also is inhibited in adipose tissues, or glucose uptake into adipose tissues is inhibited, so that accumulation of fat within adipocytes is suppressed. Therefore, various diseases or symptoms having a relation to insulin resistance can be prevented or alleviated.

The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes; preventing or treating obesity; scavenging free radicals; stimulating the immune system; activating macrophages; preventing or treating condition mediated by macrophage activation; and modulating nitric oxide production by macrophages. Methods for using the Ascophyllum extracts of the invention are provided, as are kits comprising Ascophyllum extracts of the invention and instructions for using the extracts.

The invention provides a nano catalyst for tumor treatment, and a preparation method and application thereof. The nano catalyst provided by the invention comprises an erythrocyte membrane, and a composite nano enzyme and a photosensitizer which are coated in the erythrocyte membrane, wherein the composite nano enzyme comprises glucose oxidase and iron nanoparticles which are coated in an inner cavity of the glucose oxidase. The nano catalyst is preferentially accumulated at a target tumor site through targeted biomimetic delivery, and release of the composite nano enzyme is realized under irradiation of near infrared light. Based on high glucose uptake and a weakly acidic environment at the tumor site, glucose oxidase converts glucose into H2O2, induces iron nano particles to start an in-situ Fenton reaction, generates hydroxyl free radicals after sequential catalysis, induces tumor cells to be subjected to oxidative damage, and further kills the tumor cells. The nano catalyst not onlycan realize high-efficiency loading of the catalyst, but also can effectively prolong in-vivo circulation time, so that accurate and sustained release on a tumor focus part is realized, and a new thought and platform are provided for tumor treatment.

The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.

Various scaffolds of small molecules capable of binding to the active site of sortilin are identified by in silico methods. These scaffolds include norbornene anhydride amino acid adducts, phenyl-amide-acids of benzyl substituted glutaric acids, and 2-substituted 3-oxo-1,2,3,4-tetrahydro-2-quinoxalines. These sortilin ligands increase the uptake of glucose in 3T3L1 cells and can be employed in compositions to increase uptake of glucose for the treatment of diabetic patents.

A scanner (10) is used to provide images for automated diagnoses of neurodegenerative diseases, such as Alzheimer s disease. The images are registered (90) to a template (78). The aligned image is analyzed (60) in relation to reference image data (76, 80) which has been registered to the template which is contained in a knowledge maintenance engine (70) for similar patterns of hypo-intensity that would indicate (in the case of an FDG tracer) reduced glucose uptake in the brain. The most appropriate reference images for the analysis of the present study are chosen by a filter (74). The present study is then given a dementia score (84) as a diagnostic feature vector that indicates to a clinician the type and severity of the ailment based on the analysis. The scanner (10) can produce PET or other metabolic and MR images for diagnosis. The MR can be used to measure blood flow rate into the brain. From the blood flow rate and the metabolic image, tracer, e.g. FDG, uptake maps can be generated for use in the automated diagnoses.

A buckwheat extract comprising at least myo-inositol, D-chiro-inositol, a fagopyritol, one MAPK-stimulating compound, and one glucose-uptake inhibiting compound. A substantially pure glucose-uptake inhibiting compound selected from a buckwheat extract. A method for providing a glucose-uptake inhibiting extract from buckwheat seed comprising first contacting said buckwheat seed with a non-polar solvent, then contacting said buckwheat seed with a polar aprotic solvent, and then finally contacting said buckwheat seed with a third solvent. The third solvent may be a polar aprotic solvent or a polar protic solvent. The extract produced by contacting buckwheat seed with the third solvent is dried to remove the solvent therefrom. Compositions comprising dried glucose-uptake inhibiting buckwheat extracts and purified compounds therefrom.

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.

The invention provides a drug composite for curing diabetes and a preparation method and an application thereof, and belongs to the field of medicine. The drug composite for curing diabetes comprises at least one of Inoscavin C, 7,3'-dihydroxyl-5'-methoxyl isoflavone, 7,8-dihydroxy coumarin and 3,4-dihydroxy benzylidene acetone, and medically acceptable carriers or auxiliary materials. The application of the drug composite is wide and comprises that the drug composite is applied to preparing an agonist for promoting glucose uptake, preparing an agonist for using adenosine phosphate to activate protein kinase, preparing an agonist of glucose transport protein 4, and preparing a drug for curing or preventing diseases caused by metabolic disturbance or preparing health care products, a new treatment means and thought are provided for treatment of diseases caused by metabolic disturbance, and meanwhile new medical value of phellinus igniarius is further developed.

The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders.

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.